We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.675 | 4.35 | 5.00 | - | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 08/9/2020 07:23 | They have only just released these interim results and no COVID peer review as yet. This will support the discussions with regulators most importantly but the safety element is key so a great RNS and clearly interferon beta will be effective for multiple infections affecting the lung. I imagine discussions will now accelerate and countries with large infection rates likeIndia and Brazil should be keener than most. The leaders aren't the types to go the usual routes and take their time. | tickboo | |
| 08/9/2020 07:22 | well a step in the right direction, for sure - but a baby step when what is needed (esp re covid) is giant steps NOW! | sloppyjoe2 | |
| 08/9/2020 07:21 | Excellent update. We should break through that 250p ceiling this morning. I'm topping up. | hodhasharon | |
| 08/9/2020 07:20 | A little more... it's OK !!Not earth shattering, put it that way. | amaretto1 | |
| 08/9/2020 07:16 | and what's next? no mention of a JV, more trials, licensing or other commercialisation? hugely disappointing. | sloppyjoe2 | |
| 08/9/2020 07:14 | A big hmmmmm to that RNS. Notably lacking in any mention of the primary endpoints. | mirako | |
| 08/9/2020 07:12 | What were you expecting? | losses |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
